Development asset linked to Alphapharm in public FDA and regional records.
pharma · Scabies · Bioequivalence trial in healthy volunteers
Alphapharm
Alphapharm Pty Ltd
Alphapharm drug portfolio — 80 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Level 1, 30 The Bond, 30-34 Hickson Road, Millers Point, NSW 2000, AU HQ
1982 Founded
187 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Level 1, 30 The Bond, 30-34 Hickson Road, Millers Point, NSW 2000, AU
- Founded
- 1982
- Employees
- 187
- Programs
- 30
- Drugs
- 235
- Patents
- 12
Alphapharm pipeline
Portfolio lens on 80 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Alphapharm drug portfolio — 80 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
abiraterone
Antineoplastic and immunomodulating agents (L02)Antineoplastic and immunomodulating agents (L02) compound in Alphapharm's portfolio. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Steroid 5-alpha-reductase inhibitor
-
Development asset linked to Alphapharm in public FDA and regional records. Mechanism: GABA-A receptor; anion channel positive modulator.
- Mechanism
- GABA-A receptor; anion channel positive modulator
-
US regulatory status: approved. Molecular target: Maltase-glucoamylase.
- Target
- Maltase-glucoamylase
- Mechanism
- Pancreatic alpha-amylase inhibitor
-
Development asset linked to Alphapharm in public FDA and regional records. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
Development asset linked to Alphapharm in public FDA and regional records.
-
Development asset linked to Alphapharm in public FDA and regional records.
-
allopurinol
Musculo-skeletal system (M04)US regulatory status: approved. Molecular target: Xanthine dehydrogenase/oxidase.
- Target
- Xanthine dehydrogenase/oxidase
- Mechanism
- Xanthine dehydrogenase inhibitor
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
ambrisentan
Cardiovascular system (C02)US regulatory status: approved. Molecular target: Endothelin receptor, ET-A/ET-B.
- Target
- Endothelin receptor, ET-A/ET-B
- Mechanism
- Endothelin receptor, ET-A/ET-B antagonist
-
Development asset linked to Alphapharm in public FDA and regional records. Mechanism: HERG blocker.
- Mechanism
- HERG blocker
-
US regulatory status: approved. Molecular target: Dopamine receptors; D2 & D3.
- Target
- Dopamine receptors; D2 & D3
- Mechanism
- Serotonin (5-HT) receptor antagonist
-
Development asset linked to Alphapharm in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
amlodipine
Cardiovascular system (C09)Cardiovascular system (C09) compound in Alphapharm's portfolio. Mechanism: Voltage-gated L-type calcium channel blocker.
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
Development asset linked to Alphapharm in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to Alphapharm in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
-
arginine
Various (V03)Various (V03) compound in Alphapharm's portfolio.
-
aripiprazole
Nervous system (N05)US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Beta-1 adrenergic receptor.
- Target
- Beta-1 adrenergic receptor
- Mechanism
- Beta-1 adrenergic receptor antagonist
-
Development asset linked to Alphapharm in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
azathioprine
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.
- Target
- Amidophosphoribosyltransferase
- Mechanism
- Amidophosphoribosyltransferase inhibitor
-
US regulatory status: approved. Molecular target: GABA-B receptor.
- Target
- GABA-B receptor
- Mechanism
- GABA-B receptor agonist
-
Development asset linked to Alphapharm in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
bimatoprost
Sensory organs (S01)US regulatory status: approved. Molecular target: Prostaglandin F2-alpha receptor.
- Target
- Prostaglandin F2-alpha receptor
- Mechanism
- Prostanoid FP receptor agonist
-
Development asset linked to Alphapharm in public FDA and regional records. Mechanism: Beta-1 adrenergic receptor antagonist.
- Mechanism
- Beta-1 adrenergic receptor antagonist
-
bosentan
Cardiovascular system (C02)US regulatory status: approved. Molecular target: Endothelin receptor, ET-A/ET-B.
- Target
- Endothelin receptor, ET-A/ET-B
- Mechanism
- Endothelin receptor, ET-A/ET-B antagonist
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Alphapharm in public FDA and regional records. Molecular target: Type-1 angiotensin II receptor.
- Target
- Type-1 angiotensin II receptor
- Mechanism
- Type-1 angiotensin II receptor antagonist
-
Development asset linked to Alphapharm in public FDA and regional records.
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-1.
- Target
- Adrenergic receptor alpha-1
- Mechanism
- Adrenergic receptor beta antagonist
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to Alphapharm in public FDA and regional records.
-
Development asset linked to Alphapharm in public FDA and regional records.
-
Development asset linked to Alphapharm in public FDA and regional records.
-
Development asset linked to Alphapharm in public FDA and regional records.
-
Development asset linked to Alphapharm in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
Development asset linked to Alphapharm in public FDA and regional records.
-
cinacalcet
Systemic hormonal preparations (H05)Systemic hormonal preparations (H05) compound in Alphapharm's portfolio. Mechanism: Calcium sensing receptor positive allosteric modulator.
- Mechanism
- Calcium sensing receptor positive allosteric modulator
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
Development asset linked to Alphapharm in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
Development asset linked to Alphapharm in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Alphapharm in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
clopidogrel
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in Alphapharm's portfolio. Mechanism: Purinergic receptor P2Y12 antagonist.
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
Development asset linked to Alphapharm in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
Development asset linked to Alphapharm in public FDA and regional records.
-
Development asset linked to Alphapharm in public FDA and regional records. Molecular target: Prothrombin.
- Target
- Prothrombin
- Mechanism
- Thrombin inhibitor
-
dasatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Bcr/Abl fusion protein.
- Target
- Bcr/Abl fusion protein
- Mechanism
- SRC inhibitor
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to Alphapharm in public FDA and regional records.
-
Development asset linked to Alphapharm in public FDA and regional records. Mechanism: Carbonic anhydrase II inhibitor.
- Mechanism
- Carbonic anhydrase II inhibitor
-
Development asset linked to Alphapharm in public FDA and regional records.
-
Development asset linked to Alphapharm in public FDA and regional records.
-
Development asset linked to Alphapharm in public FDA and regional records. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Matrix metalloproteinase 8 inhibitor
-
duloxetine
Nervous system (N06)Nervous system (N06) compound in Alphapharm's portfolio. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
Development asset linked to Alphapharm in public FDA and regional records. Mechanism: Angiotensin-converting enzyme inhibitor.
- Mechanism
- Angiotensin-converting enzyme inhibitor
-
Development asset linked to Alphapharm in public FDA and regional records.
-
enoxaparin sodium
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Antithrombin-III.
- Target
- Antithrombin-III
- Mechanism
- Antithrombin-III activator
-
entecavir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA polymerase/reverse transcriptase.
- Target
- DNA polymerase/reverse transcriptase
- Mechanism
- DNA polymerase/reverse transcriptase inhibitor
-
Development asset linked to Alphapharm in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Mineralocorticoid receptor.
- Target
- Mineralocorticoid receptor
- Mechanism
- Mineralocorticoid receptor antagonist
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
Development asset linked to Alphapharm in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
esomeprazole
Alimentary tract and metabolism (A02)Alimentary tract and metabolism (A02) compound in Alphapharm's portfolio. Mechanism: Potassium-transporting ATPase inhibitor.
- Mechanism
- Potassium-transporting ATPase inhibitor
-
US regulatory status: approved. Molecular target: DNA topoisomerase II.
- Target
- DNA topoisomerase II
- Mechanism
- DNA topoisomerase II inhibitor